Pink Sheets: OSI Pharmaceuticals Inc (OSIPR) news stock charts
OSI Pharmaceuticals Inc (OSIPR/OSIPR.PK) Penny Investment Summary:
OSI Pharmaceuticals, Inc., a biotechnology company, discovers, develops, and commercializes molecular targeted therapies for oncology, diabetes, and obesity in the United States and internationally. Its flagship product, Tarceva (erlotinib) is a small molecule inhibitor of the epidermal growth factor receptor, which is used for the treatment of advanced non-small cell lung cancer, as well as for the treatment of patients with locally advanced and metastatic pancreatic cancer in combination with the chemotherapy agent, gemcitabine. The company also offers Macugen for the treatment of neovascular age-related macular degeneration; and Novantrone, an anthracenedione used as an intravenous chemot...OSI PHARMACEUTICALS INC-RT (OSIPR:OTC)
Snapshot of OSI PHARMACEUTICALS INC-RT (OSIPR)
|
OPEN
--
|
PREVIOUS CLOSE
--
|
|
|
DAY HIGH
--
|
DAY LOW
--
|
|
|
52 WEEK HIGH
-- - --
|
52 WEEK LOW
-- - --
|
|
|
MARKET CAP
--
|
AVERAGE VOLUME 10 D
0.0
|
|
|
EPS TTM
--
|
SHARES OUTSTANDING
0.0
|
|
|
OSIPR Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
related news
related news
Key developments for OSI PHARMACEUTICALS INC-RT (OSIPR)
OSI Pharmaceuticals Inc. Presents at BioTrinity 2010, Apr-12-2010 through Apr-14-2010. Venue: Newbury Racecourse plc, The Racecourse, Newbury, Berkshire RG14 7NZ, United Kingdom.
Astellas US Holding Inc. filed a lawsuit in the Delaware Court of Chancery against OSI Pharmaceuticals Inc. and its directors seeking, among other things, declaratory and injunctive relief enjoining OSI and its directors from engaging in any action or inaction, including applying OSI's "poison pill" rights plan, that has the effect of improperly impeding, thwarting, frustrating or interfering with the tender offer in a manner inconsistent with the directors' fiduciary duties. The Astellas tender offer represents a significant premium of over 40% to OSI's closing share price of $37.02 on February 26, 2010, a 53% premium to its three-month average of $34.01 per share and a 31% premium to its 52-week high of $39.66 per share. The offer is not conditioned on financing. The offer is conditioned on there being validly tendered and not withdrawn at least a majority of the total number of OSI shares outstanding on a fully diluted basis, OSI's board of directors redeeming or invalidating its "poison pill" shareholder rights plan and receipt of regulatory approvals and customary closing conditions as described in the Offer to Purchase.
OSI Pharmaceuticals Inc. expected to Report Q1 2010 Results on April 26, 2010. This event was calculated by Capital IQ (Created on February 23, 2010).
OSI Pharmaceuticals Inc financial resources
OSIPR Competitors
| Company | Last | Change |
| Abraxis Bioscience Inc | $51.51 USD | -0.24 |
| Celera Corp | $6.92 USD | +0.04 |
| Onyx Pharmaceuticals Inc | $32.21 USD | +0.06 |
| Regeneron Pharmaceuticals Inc | $23.77 USD | -0.92 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | OSIPR | Industry Range |
| Price/Earnings | 46.9x |
|
| Price/Sales | 8.0x |
|
| Price/Book | 4.8x |
|
| Price/Cash Flow | 44.7x |
|
| TEV/Sales | 6.2x |
|
|
OSIPR |
||
OSIPR transactions
| Type Date |
Target |
|
Merger/Acquisition
February 12, 2010 |
-- |